Why is ERIS Lifescience falling/rising?

As of 15-Sep, ERIS Lifesciences Ltd's stock price is currently at 1,660.00, reflecting a decrease of 15.0 points or 0.9%. The stock has been underperforming recently, having fallen consecutively for the last three days, resulting in a total decline of 3.42% during this period. Despite this short-term downturn, the stock has shown strong performance over the longer term, with a year-to-date increase of 21.27% and a remarkable 137.50% rise over the past three years. The company benefits from high management efficiency, a low debt-to-EBITDA ratio, and strong institutional holdings, which contribute positively to its fundamentals and may support its price in the long run.
In the broader market context, ERIS Lifesciences has underperformed compared to the Sensex, which has gained 1.24% over the past week while the stock has declined by 3.04%. This disparity highlights the stock's recent struggles despite its strong historical performance. The rising investor participation, indicated by a significant increase in delivery volume, suggests that there may be interest from investors looking for potential recovery, but the current trend indicates a cautious sentiment in the short term. Overall, while the stock has solid fundamentals, its recent price movement reflects a challenging market environment and short-term volatility.